Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

REFERENCES

• Mathers WD. Why the eye becomes dry: A cornea and lacrimal gland feedback model. CLAO J. 2000;26:159–165.
   PubMedGoogle Scholar
• Mainville N, Jordan DR. Etiology of tearing: A retrospective analysis of referrals to a tertiary care oculoplastics practice. Ophthal Plast Reconstr Surg. 2011; 27:155–157.
   PubMed Web of Science ®Google Scholar
• Versura P, Campos EC. Menopause and dry eye. A possible relationship. Gynecol Endocrinol. 2005;20:289–298.
   PubMed Web of Science ®Google Scholar
• Lasudry J. [The pathology of ocular syndromes caused by toxicity]. Bull Soc Belge Ophtalmol. 2007:155–178.
   Google Scholar
• Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol. 2010;22:56–60.
   PubMedGoogle Scholar
• Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: Saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30:343–375.
   PubMed Web of Science ®Google Scholar
• Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97–148.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28:3784–3796.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72:7–25.
   PubMed Web of Science ®Google Scholar
• Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer. 2001;92:37–45.
   Google Scholar
• Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892–897.
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.
   PubMed Web of Science ®Google Scholar
• Karellas A, Vedantham S. Breast cancer imaging: A perspective for the next decade. Med Phys. 2008;35:4878–4897.
   PubMedGoogle Scholar
• Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol. 2002;37:1–28.
   PubMed Web of Science ®Google Scholar
• Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res. 2004;78:861–871.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kinoshita Y, Tachibana M, Matsushima Y, Kobayashi Y, Adachi W, Sotozono C, Kinoshita S. Expression of sex steroid hormone receptors in human cornea. Curr Eye Res. 2001;22:28–33.
   PubMed Web of Science ®Google Scholar
• Spelsberg H, Klueppel M, Reinhard T, Glaeser M, Niederacher D, Beckmann MW, Sundmacher R. Detection of oestrogen receptors (ER) alpha and beta in conjunctiva, lacrimal gland, and tarsal plates. Eye. 2004;18:729–733.
   Google Scholar
• Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand. 2000;78:146–153.
   PubMedGoogle Scholar
• Marin-Castano ME, Elliot SJ, Potier M, Karl M, Striker LJ, Striker GE, Csaky KG, Cousins SW. Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:50–59.
   PubMed Web of Science ®Google Scholar
• Munaut C, Lambert V, Noel A, Frankenne F, Deprez M, Foidart JM, Rakic JM. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001;85:877–882.
   PubMed Web of Science ®Google Scholar
• Sullivan DA. Tearful relationships? Sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. Ocul Surf. 2004;2:92–123.
   PubMedGoogle Scholar
• Auw-Haedrich C, Feltgen N. Estrogen receptor expression in meibomian glands and its correlation with age and dry-eye parameters. Graefes Arch Clin Exp Ophthalmol. 2003;241:705–709.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Harvey JT, Hewlett B. Immunohistochemical evidence for estrogen receptors in meibomian glands. Ophthalmology. 2000;107:180–184.
   PubMed Web of Science ®Google Scholar
• Garcia-Segura LM. Aromatase in the brain: Not just for reproduction anymore. J Neuroendocrinol. 2008;20:705–712.
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, Whiteside GT, Brandon NJ. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol. 2009;2:215–236.
   PubMedGoogle Scholar
• Morissette M, Le Saux M, D’Astous M, Jourdain S, Al Sweidi S, Morin N, Estrada-Camarena E, Mendez P, Garcia-Segura LM, Di Paolo T. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol. 2008;108:327–338.
   Google Scholar
• Vasudevan N, Pfaff DW. Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front Neuroendocrinol. 2008;29:238–257.
   PubMed Web of Science ®Google Scholar
• Boon WC, Chow JD, Simpson ER. The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res.181:209–232.
   Google Scholar
• Speroff L, Fritz M. Menopause and the perimenopausal transition. In Clinical Gynecologic Endocrinology and Infertility, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:621–688.
   Google Scholar
• Hiscox S, Davies EL, Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas. 2009;63:275–279.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Griggs JJ. Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010;19:639–647.
   Google Scholar
• Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26:798–805.
   PubMed Web of Science ®Google Scholar
• Mabuchi F, Sakurada Y, Kashiwagi K, Yamagata Z, Iijima H, Tsukahara S. Estrogen receptor beta gene polymorphism and intraocular pressure elevation in female patients with primary open-angle glaucoma. Am J Ophthalmol. 2010;149:826–830 e821–e822.
   PubMedGoogle Scholar
• Vajaranant TS, Nayak S, Wilensky JT, Joslin CE. Gender and glaucoma: What we know and what we need to know. Curr Opin Ophthalmol. 2010;21:91–99.
   PubMed Web of Science ®Google Scholar
• Kang JH, Wiggs JL, Rosner BA, Hankinson SE, Abdrabou W, Fan BJ, Haines J, Pasquale LR. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: Interactions with sex and postmenopausal hormone use. Invest Ophthalmol Vis Sci. 2010;51:971–979.
   PubMed Web of Science ®Google Scholar
• Tint NL, Alexander P, Tint KM, Vasileiadis GT, Yeung AM, Azuara-Blanco A. Hormone therapy and intraocular pressure in nonglaucomatous eyes. Menopause. 2010;17:157–160
   PubMed Web of Science ®Google Scholar
• Deschenes MC, Descovich D, Moreau M, Granger L, Kuchel GA, Mikkola TS, Fick GH, Chemtob S, Vaucher E, Lesk MR. Postmenopausal hormone therapy increases retinal blood flow and protects the retinal nerve fiber layer. Invest Ophthalmol Vis Sci.2010;51:2587–2600.
   PubMed Web of Science ®Google Scholar
• Gawecki M, Doroszkiewicz M, Rydzewski J. Age related macular degeneration and presence of posterior vitreous detachment. Klin Oczna. 2010;112:210–212
   Google Scholar
• Boekhoorn SS, Vingerling JR, Uitterlinden AG, Van Meurs JB, van Duijn CM, Pols HA, Hofman A, de Jong PT. Estrogen receptor alpha gene polymorphisms associated with incident aging macula disorder. Invest Ophthalmol Vis Sci. 2007;48:1012–1017.
   PubMedGoogle Scholar
• Edwards DR, Gallins P, Polk M, Ayala-Haedo J, Schwartz SG, Kovach JL, Spencer K, Wang G, Agarwal A, Postel EA, Haines JL, Pericak-Vance M, Scott WK. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms. Invest Ophthalmol Vis Sci. 2010;51:1873–1879.
   PubMed Web of Science ®Google Scholar
• Feskanich D, Cho E, Schaumberg DA, Colditz GA, Hankinson SE. Menopausal and reproductive factors and risk of age-related macular degeneration. Arch Ophthalmol. 2008;126:519–524.
   PubMedGoogle Scholar
• Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol. 2010;118:294–299.
   Google Scholar
• Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol. 2010;117:139–145.
   PubMedGoogle Scholar
• Winters-Stone KM, Togrimson BM, Horak FB, Eisner A, Leo MC, Nail LM, Chui SY, Luoh SW. Identifying factors associated with falls in postmenopausal breast cancer survivors: A multi-disciplinary approach. Arch Phys Med Rehab. 2011;92:646–652.
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562.
   PubMed Web of Science ®Google Scholar
• Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat.2011;125:191–200.
   PubMed Web of Science ®Google Scholar
• Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol. 2007;106:168–172.
   Google Scholar
• Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: A nursing perspective. Clin J Oncol Nurs. 2008;12:213–221.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–537.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9:1143–1148.
   PubMed Web of Science ®Google Scholar
• Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238–244.
   PubMed Web of Science ®Google Scholar
• Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. Special report: Consensus conference III. Image-detected breast cancer: State-of-the-art diagnosis and treatment. J Am Coll Surg. 2009;209:504–520.
   Google Scholar
• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019–8026.
   PubMed Web of Science ®Google Scholar
• Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res. 2009;11:205
   PubMedGoogle Scholar
• Garcia-Estevez L, Tusquets I, Alvarez I, Rodriguez C, Fernandez Y, Segui MA, Garcia-Mata J, Lluch A. Supportive care for patients with early breast cancer. Clin Transl Oncol. 2010;12:32–42.
   Google Scholar
• Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107:167–180.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–621.
   PubMed Web of Science ®Google Scholar
• Redmond N, While A. Dry eye syndrome (DES) and watering eyes. Br J Community Nurs. 2008;13:471–479.
   Google Scholar
• Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev.2010; CD006775.
   Google Scholar
• Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21:310–316.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008;85:668–674.
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, Schaffar R, Vlastos G, Wespi Y, Schafer P, Rapiti E. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat. 2010;120:519–523.
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006;26:853–867.
   PubMed Web of Science ®Google Scholar
• Koh S, Maeda N, Ninomiya S, Watanabe H, Fujikado T, Tano Y, Hirohara Y, Mihashi T. Paradoxical increase of visual impairment with punctal occlusion in a patient with mild dry eye. J Cataract Refract Surg. 2006;32:689–691.
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–1496.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–741.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF. Reversal of resistance to oxazaphosphorines. Curr Cancer Drug Targets. 2006;6:385–407.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol. 2009;6:638–647.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology. 1983;90:1–3.
   PubMed Web of Science ®Google Scholar
• Blum RH. An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemotherapy Reports Part 3. 1975;6:247–251
   Google Scholar
• Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: A decade in review. Clin Breast Cancer. 2010;10:196–208.
   Google Scholar
• Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009;35:255–261.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353–374.
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–1183.
   PubMed Web of Science ®Google Scholar
• Tang SC. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Cancer Invest. 2009;27:206–214.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Gligorov J. Taxane therapy for early stage breast cancer. Womens Health (Lond Engl). 2006;2:99–114.
   Google Scholar
• Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: Optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol. 2010;7:22–36.
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, Geyer CE, Jr., Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–2027.
   PubMed Web of Science ®Google Scholar
• Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Munoz M, Lopez Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia-Asenjo JA, Saez A, Rios MJ, Almenar S, Peiro G, Lluch A. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363:2200–2210.
   PubMed Web of Science ®Google Scholar
• Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: A retrospective, outcomes-based survey. Curr Oncol. 2010;17:42–47.
   PubMed Web of Science ®Google Scholar
• Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer. 2005;5:455–457.
   PubMedGoogle Scholar
• McCartney E, Valluri S, Rushing D, Burgett R. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthal Plast Reconstr Surg. 2007;23:170–171.
   PubMed Web of Science ®Google Scholar
• Savar A, Esmaeli B. Re: “Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel”. Ophthal Plast Reconstr Surg. 2009;25:418–419; author reply 419.
   Google Scholar
• Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM, Newman RA. Docetaxel secretion in tears: Association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120:1180–1182.
   PubMedGoogle Scholar
• Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–507.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006;24:3619–3622.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212–1219.
   PubMed Web of Science ®Google Scholar
• Tsalic M, Gilboa M, Visel B, Miller B, Haim N. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: Underestimated dose-limiting toxicity. Med Oncol. 2006;23:57–61.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–1642.
   PubMed Web of Science ®Google Scholar
• Kuroi K, Shimozuma K. Neurotoxicity of taxanes: Symptoms and quality of life assessment. Breast Cancer. 2004;11:92–99.
   Google Scholar
• Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125:767–774.
   PubMed Web of Science ®Google Scholar
• Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15:3081–3094.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci. 2006;27:17–24
   PubMed Web of Science ®Google Scholar
• Scaioli V, Caraceni A, Martini C, Curzi S, Capri G, Luca G. Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol. 2006;77:79–87.
   PubMed Web of Science ®Google Scholar
• Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, Martini C, Scaioli V. Optic nerve disturbances: A new form of paclitaxel neurotoxicity. J Natl Cancer Inst. 1994;86:1099–1101.
   PubMed Web of Science ®Google Scholar
• Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol.2010;28:e684–e687.
   PubMed Web of Science ®Google Scholar
• Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003;80:277–279.
   PubMed Web of Science ®Google Scholar
• Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol. 2007;22:151–153.
   PubMedGoogle Scholar
• Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126:1605–1606.
   PubMed Web of Science ®Google Scholar
• Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol. 2007;125:709–710.
   PubMed Web of Science ®Google Scholar
• Ito S, Okuda M. [A case of cystic maculopathy during paclitaxel therapy]. Nippon Ganka Gakkai Zasshi.2010;114:23–27.
   Google Scholar
• Verrill M. Chemotherapy for early-stage breast cancer: A brief history. Br J Cancer. 2009;101 Suppl 1:S2–S5.
   Google Scholar
• Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep. 2003;5:114–125.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338.
   PubMed Web of Science ®Google Scholar
• Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand. 2000;78:110–113.
   Google Scholar
• Fezza JP, Wesley RE, Klippenstein KA. The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. Ophthalmic Surg Lasers. 1999;30:105–108.
   Google Scholar
• Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye (Lond). 1998;12 (Pt 3a):343–349.
   Google Scholar
• Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol. 1995;90:1–6
   PubMed Web of Science ®Google Scholar
• Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg. 2003;19:216–224.
   Web of Science ®Google Scholar
• Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. Cancer Invest. 1990;8:459–465.
   PubMed Web of Science ®Google Scholar
• Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: A review of the literature. Cancer. 1981;48:1539–1549.
   PubMed Web of Science ®Google Scholar
• Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9:143–144.
   PubMedGoogle Scholar
• Hussain MI. Ocular irritation from low-dose methotrexate. Cancer. 1982;50:605.
   PubMed Web of Science ®Google Scholar
• Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group. Ann Oncol. 2003;14:833–842.
   PubMed Web of Science ®Google Scholar
• Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010;10:228
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668–675.
   PubMed Web of Science ®Google Scholar
• Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63–69.
   PubMedGoogle Scholar
• Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487.
   PubMed Web of Science ®Google Scholar
• Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008;8:392–401.
   PubMed Web of Science ®Google Scholar
• Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: Overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9:148–162.
   Google Scholar
• Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma S, Chia S, Wang B, Rayson D. Optimizing the management of HER2-positive early breast cancer: The clinical reality. Curr Oncol. 2010;17:20–33.
   Google Scholar
• Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21:2153–2160.
   Google Scholar
• Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM. Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells. Biochemistry. 1995;34:8474–8480.
   PubMed Web of Science ®Google Scholar
• Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol. 2010;28:2024–2031.
   PubMed Web of Science ®Google Scholar
• Taillibert S, Voillery D, Bernard-Marty C. Chemobrain: Is systemic chemotherapy neurotoxic? Curr Opin Oncol. 2007;19:623–627.
   PubMed Web of Science ®Google Scholar
• Marin AP, Sanchez AR, Arranz EE, Aunon PZ, Baron MG. Adjuvant chemotherapy for breast cancer and cognitive impairment. South Med J. 2009;102:929–934.
   PubMed Web of Science ®Google Scholar
• Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: Mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–280.
   PubMedGoogle Scholar
• Raffa RB, Tallarida RJ. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’. J Clin Pharm Ther. 2010;35:249–255.
   PubMed Web of Science ®Google Scholar
• Weiss B. Evaluation of multiple neurotoxic outcomes in cancer chemotherapy. Adv Exp Med Biol. 2010;678:96–112.
   Google Scholar
• Myers JS. Neuropsychologic testing for chemotherapy-related cognitive impairment. Adv Exp Med Biol. 2010;678:55–69.
   PubMed Web of Science ®Google Scholar
• Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007;34:997–1005.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Wijayaratne A, Chang CY, Norris JD. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol. 2002;90:35F–43F.
   PubMed Web of Science ®Google Scholar
• Musa MA, Khan MO, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14:1249–1261.
   PubMed Web of Science ®Google Scholar
• Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163–181.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 2010;10:620–628.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: Mechanisms of efficiency and resistance. Adv Exp Med Biol. 2008;630:206–219.
   PubMed Web of Science ®Google Scholar
• Briest S, Wolff AC. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Rev Anticancer Ther. 2007;7:1243–1253.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359–2364.
   PubMed Web of Science ®Google Scholar
• Agatonovic-Kustrin S, Turner JV. Molecular structural characteristics of estrogen receptor modulators as determinants of estrogen receptor selectivity. Mini Rev Med Chem. 2008;8:943–951.
   Google Scholar
• Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer. 2009;9 Suppl 1:S28–S36.
   Google Scholar
• Maenpaa H, Saransaari P, Tahti H. Kinetics of inhibition of glutamate uptake by antioestrogens. Pharmacol Toxicol. 2003;93:174–179.
   Google Scholar
• Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol. 2005;95:75–81.
   PubMed Web of Science ®Google Scholar
• Messinis IE. Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod Update. 2006;12:557–571.
   PubMed Web of Science ®Google Scholar
• Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009;9 Suppl 1:S6–S17.
   Google Scholar
• Nordman IC, Dalley DN. Breast cancer in men: Should aromatase inhibitors become first–line hormonal treatment? Breast J. 2008;14:562–569.
   PubMed Web of Science ®Google Scholar
• Harlan LC, Zujewski JA, Goodman MT, Stevens JL. Breast cancer in men in the United States: A population-based study of diagnosis, treatment, and survival. Cancer. 2010;116:3558–3568
   PubMed Web of Science ®Google Scholar
• Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: Summary and research recommendations. J Clin Oncol. 2010;28:2114–2122.
   PubMed Web of Science ®Google Scholar
• Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: An update in diagnosis, treatment and molecular profiling. Maturitas. 2010;65:308–314.
   Google Scholar
• Moss RL, Gu Q, Wong M. Estrogen: Nontranscriptional signaling pathway. Recent Prog Horm Res. 1997;52:33–68; discussion 68–39.
   Google Scholar
• Woolley CS. Acute effects of estrogen on neuronal physiology. Annu Rev Pharmacol Toxicol. 2007;47:657–680.
   PubMed Web of Science ®Google Scholar
• Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol. 2007;213:610–617.
   PubMed Web of Science ®Google Scholar
• Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008;27:284–330.
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril. 2006;86:S187–S193.
   Google Scholar
• Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213.
   PubMed Web of Science ®Google Scholar
• Racette L, Casson PR, Claman P, Zackon DH, Casson EJ. An investigation of the visual disturbances experienced by patients on clomiphene citrate. Fertil Steril. 2010;93:1169–1172.
   PubMed Web of Science ®Google Scholar
• Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995;113:482–484.
   PubMedGoogle Scholar
• Bernstein HN. Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin. 1970;10:553–619.
   PubMedGoogle Scholar
• Roch LM, 2nd Gordon, DL, Barr AB, Paulsen CA. Visual changes associated with clomiphene citrate therapy. Arch Ophthalmol. 1967;77:14–17.
   Google Scholar
• Casper RF, Mitwally MF. Review: Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006;91:760–771.
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance. Curr Oncol Rep. 2010;12:7–15.
   PubMed Web of Science ®Google Scholar
• Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009;55:1770–1782.
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, Flaws JA. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat. 2004;85:89–97.
   Google Scholar
• Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach? Eur J Cancer. 2009;45:2274–2283.
   PubMed Web of Science ®Google Scholar
• Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab. 2007;8:297–306.
   PubMed Web of Science ®Google Scholar
• McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65:177–179.
   PubMed Web of Science ®Google Scholar
• Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981;88:89–93.
   PubMed Web of Science ®Google Scholar
• Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996;14:1018–1026.
   PubMed Web of Science ®Google Scholar
• Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N, Kaufmann D. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493–501.
   PubMed Web of Science ®Google Scholar
• Chung H, Kim D, Ahn SH, Kim JG, Lee JY, Lim JY, Yoon YH. Early detection of tamoxifen-induced maculopathy in patients with low cumulative doses of tamoxifen. Ophthalmic Surg Lasers Imaging. 2010;41:e1–e5.
   Google Scholar
• Longstaff S, Sigurdsson H, O’Keeffe M, Ogston S, Preece P. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol. 1989;25:1805–1808.
   PubMedGoogle Scholar
• Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, Prager T, Pardo G. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997;11 (Pt 3):295–297.
   Google Scholar
• Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69:2961–2964.
   PubMed Web of Science ®Google Scholar
• Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: A prospective study. Eye. 1999;13 (Pt 6):729–733.
   Google Scholar
• Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994;117:772–775.
   PubMed Web of Science ®Google Scholar
• Lazzaroni F, Scorolli L, Pizzoleo CF, Savini G, De Nigris A, Giosa F, Meduri RA. Tamoxifen retinopathy: Does it really exist? Graefes Arch Clin Exp Ophthalmol. 1998;236:669–673.
   PubMedGoogle Scholar
• Eisner A, Falardeau J, Toomey MD, Vetto JT. Retinal hemorrhages in anastrozole users. Optom Vis Sci. 2008;85:301–308.
   PubMed Web of Science ®Google Scholar
• Eisner A, Toomey MD, Falardeau J, Samples JR, Vetto JT. Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat. 2007;106:161–170.
   PubMed Web of Science ®Google Scholar
• Eisner A, Demirel S. Variability in short-wavelength automated perimetry among peri- or postmenopausal women: A dependence on phyto-oestrogen consumption? Acta Ophthalmol. 2011;89:e217–e224.
   Google Scholar
• Eisner A, Austin DF, Samples JR. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol. 2004;88:125–130.
   PubMed Web of Science ®Google Scholar
• Eisner A, Thielman EJ, Falardeau J, Vetto JT. Vitreo-retinal traction and anastrozole use. Breast Cancer Res Treat. 2009;117:9–16.
   PubMed Web of Science ®Google Scholar
• Eisner A, Toomey MD. The color appearance of stimuli detected via short-wavelength-sensitive cones: Comparisons with visual adaptation and visual field data for peri- or post-menopausal women under 70 years of age. Vision Res. 2008;48:2663–2672.
   Google Scholar
• Eisner A, Toomey MD, Incognito LJ, O’Malley J P, Samples JR. Contrasting blue-on-yellow with white-on-white visual fields: Roles of visual adaptation for healthy peri- or postmenopausal women younger than 70 years of age. Invest Ophthalmol Vis Sci. 2006;47:5605–5614.
   Google Scholar
• Eisner A, Incognito LJ. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vision Res. 2006;46:1816–1822.
   PubMedGoogle Scholar
• Chung SE, Kim SW, Chung HW, Kang SW. Estrogen antagonist and development of macular hole. Korean J Ophthalmol. 2010;24:306–309.
   PubMedGoogle Scholar
• Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005;26:101–105.
   PubMedGoogle Scholar
• Reasor MJ, Kacew S. Drug-induced phospholipidosis: Are there functional consequences? Exp Biol Med (Maywood). 2001;226:825–830.
   PubMed Web of Science ®Google Scholar
• Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15:541–548.
   PubMedGoogle Scholar
• Parkkari M, Paakkala AM, Salminen L, Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: A randomized follow-up study. Acta Ophthalmol Scand. 2003;81:495–499.
   PubMedGoogle Scholar
• Muftuoglu O, Ucakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens. 2006;32:228–232.
   PubMedGoogle Scholar
• Wang L, Wang S, Yin JJ, Fu PP, Yu H. Light-induced toxic effects of tamoxifen: A chemotherapeutic and chemopreventive agent. J Photochem Photobiol A Chem. 2009;201:50–56.
   Google Scholar
• Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388.
   Google Scholar
• Vogel VG. The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009;9:51–60.
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;60:167–172.
   PubMed Web of Science ®Google Scholar
• Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen and cataracts: A null association. Breast Cancer Res Treat. 2004;87:189–196.
   Google Scholar
• Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol. 2000;18:3487–3494.
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Jacob TJ, Hardy SP, Higgins CF, Valverde MA. Lens opacification by antioestrogens: Tamoxifen vs ICI 182,780. Br J Pharmacol. 1995;115:1347–1348.
   Google Scholar
• Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25:127–205.
   PubMed Web of Science ®Google Scholar
• Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 1993;53:3919–3924.
   PubMed Web of Science ®Google Scholar
• Young MA, Tunstall MJ, Kistler J, Donaldson PJ. Blocking chloride channels in the rat lens: Localized changes in tissue hydration support the existence of a circulating chloride flux. Invest Ophthalmol Vis Sci. 2000;41:3049–3055.
   Google Scholar
• Zhang JJ, Jacob TJ. Volume regulation in the bovine lens and cataract. The involvement of chloride channels. J Clin Invest. 1996;97:971–978.
   PubMed Web of Science ®Google Scholar
• Borg JJ, Yuill KH, Hancox JC, Spencer IC, Kozlowski RZ. Inhibitory effects of the antiestrogen agent clomiphene on cardiac sarcolemmal anionic and cationic currents. J Pharmacol Exp Ther. 2002;303:282–292.
   Google Scholar
• Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, Gill DR, Hyde SC, Trezise AE, Higgins CF. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest. 1994;94:1690–1697.
   PubMed Web of Science ®Google Scholar
• Stifter E, Sacu S, Weghaupt H. Functional vision with cataracts of different morphologies: Comparative study. J Cataract Refract Surg. 2004;30:1883–1891.
   PubMedGoogle Scholar
• Wood J, Chaparro A, Anstey K, Lacherez P, Chidgey A, Eisemann J, Gaynor A, La P. Simulated visual impairment leads to cognitive slowing in older adults. Optom Vis Sci. 2010;87:1037–1043.
   PubMed Web of Science ®Google Scholar
• Ashford AR, Donev I, Tiwari RP, Garrett TJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer. 1988;61:33–35.
   PubMed Web of Science ®Google Scholar
• Colley SM, Elston JS. Tamoxifen optic neuropathy. Clin Experiment Ophthalmol. 2004;32:105–106.
   PubMed Web of Science ®Google Scholar
• Pugesgaard T, Von Eyben FE. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer. 1986;58:383–386.
   PubMed Web of Science ®Google Scholar
• Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: A prospective study. Eur J Ophthalmol. 1995;5:230–234.
   PubMedGoogle Scholar
• Eisner A, O’Malley JP, Incognito LJ, Toomey MD, Samples JR. Small optic cup sizes among women using tamoxifen: Assessment with scanning laser ophthalmoscopy. Curr Eye Res. 2006;31:367–379.
   PubMed Web of Science ®Google Scholar
• Mourits MJ, de Vries EG, ten Hoor KA, van der Zee AG, Willemse PH. Beware of amenorrhea during tamoxifen: It may be a wolf in sheep’s clothing. J Clin Oncol. 2007;25:3787–3788; author reply 3788–3789.
   Google Scholar
• Weinstein M, Gorrindo T, Riley A, Mormino J, Niedfeldt J, Singer B, Rodriguez G, Simon J, Pincus S. Timing of menopause and patterns of menstrual bleeding. Am J Epidemiol. 2003;158:782–791.
   PubMedGoogle Scholar
• Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L. [Tamoxifen retinopathy: A case series of clinical and functional data]. Ophthalmologe. 2008;105:544–549.
   PubMed Web of Science ®Google Scholar
• Salomao SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res. 2007;32:345–352.
   PubMed Web of Science ®Google Scholar
• Eisner A, Samples JR, Campbell HM, Cioffi GA. Foveal adaptation abnormalities in early glaucoma. J Opt Soc Am A Opt Image Sci Vis. 1995;12:2318–2328.
   Google Scholar
• Eisner A. Longitudinal changes of visual function over 18 months: Evaluation of eyes with high-and low-risk macular degeneration characteristics. Doc Ophthalmol Proc Ser. 1993;56:175–187.
   Google Scholar
• Eisner A, Burke SN, Toomey MD. Visual sensitivity across the menstrual cycle. Vis Neurosci. 2004;21:513–531.
   Google Scholar
• Akar Y, Yucel I, Akar ME, Taskin O, Ozer HO. Menstrual cycle-dependent changes in visual field analysis of healthy women. Ophthalmologica. 2005;219:30–35.
   PubMed Web of Science ®Google Scholar
• Aydin E, Demyr Denyz H, Demyrturk F, Calpkan A, Aytan H. Effect of menopause on central retinal sensitivity. J Retina-Vitreous. 2007;15:197–201.
   Google Scholar
• Verit FF, Oguz H, Ozkul Y, Bozkurt O. Long-term effects of tibolone on ocular functions in postmenopausal women. Arch Gynecol Obstet. 2007;275:255–261.
   Google Scholar
• Lakowski R, Morton A. Acquired colour losses and oral contraceptives. Mod Probl Ophthalmol. 1978;19:314–318.
   Google Scholar
• Milano A, Dal Lago L, Sotiriou C, Piccart M, Cardoso F. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer. 2006;42:2692–2705.
   PubMed Web of Science ®Google Scholar
• Agrawal K, Onami S, Mortimer JE, Pal SK. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas. 2010;67:209–214.
   Google Scholar
• Elliot SJ, Catanuto P, Espinosa-Heidmann DG, Fernandez P, Hernandez E, Saloupis P, Korach K, Karl M, Cousins SW. Estrogen receptor beta protects against in vivo injury in RPE cells. Exp Eye Res. 2010;90:10–16.
   PubMed Web of Science ®Google Scholar
• Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, Simpkins JW, Inokuchi K, Koulen P. Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Vesl-1L/Homer 1c immunoreactive synaptic connections. Invest Ophthalmol Vis Sci. 2003;44:3155–3162.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Kitaoka Y, Munemasa Y, Ohtani-Kaneko R, Kikusui T, Uematsu A, Takeda H, Hirata K, Mori Y, Ueno S. Neuroprotective effect of 17beta-estradiol against N-methyl-D-aspartate-induced retinal neurotoxicity via p-ERK induction. J Neurosci Res. 2007;85:386–394.
   Google Scholar
• Watanabe SE, Berezovsky A, Motono M, Sacai PY, Pereira JM, Sallum JM, Gebrim LH, Salomao SR. Retinal function in patients treated with tamoxifen. Doc Ophthalmol. 2010;120:137–143.
   PubMed Web of Science ®Google Scholar
• van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treat Rev. 2010;36:54–62.
   Google Scholar
• Lonning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22:503–514.
   PubMed Web of Science ®Google Scholar
• Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: Current status and future directions. Clin Breast Cancer. 2008;8:411–417.
   PubMed Web of Science ®Google Scholar
• Petkov PI, Temelkov S, Villeneuve DL, Ankley GT, Mekenyan OG. Mechanism-based categorization of aromatase inhibitors: A potential discovery and screening tool. SAR QSAR Environ Res. 2009;20:657–678.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009;457:219–223.
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, Sharma CG, Gill SD, Kim HR, Shupp HA, Pyle JR, Madrack A, Donato AL, Cheng D, Paige JR, Jordan VC. Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007;6:2817–2827.
   PubMed Web of Science ®Google Scholar
• Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D’Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: The HOBOE trial. J Clin Oncol. 2009;27:3192–3197.
   PubMed Web of Science ®Google Scholar
• McCabe CM, Flynn HW, Jr., McLean WC, Brod RD, McDonald HR, Johnson MW, Williams GA, Mieler WF. Nonsurgical management of macular hemorrhage secondary to retinal artery macroaneurysms. Arch Ophthalmol. 2000;118:780–785.
   PubMedGoogle Scholar
• Hayreh SS, Jonas JB. Posterior vitreous detachment: Clinical correlations. Ophthalmologica. 2004;218:333–343.
   PubMed Web of Science ®Google Scholar
• Risk factors for idiopathic macular holes. The Eye Disease Case-Control Study Group. Am J Ophthalmol. 1994;118:754–761.
   Google Scholar
• Bainbridge J, Herbert E, Gregor Z. Macular holes: Vitreoretinal relationships and surgical approaches. Eye (Lond). 2008;22:1301–1309.
   PubMedGoogle Scholar
• Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA. Risk factors for posterior vitreous detachment: A case-control study. Am J Ophthalmol. 2006;142:931–937.
   PubMed Web of Science ®Google Scholar
• Evans JR, Schwartz SD, McHugh JD, Thamby-Rajah Y, Hodgson SA, Wormald RP, Gregor ZJ. Systemic risk factors for idiopathic macular holes: A case-control study. Eye. 1998;12 (Pt 2):256–259.
   Google Scholar
• Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567.
   PubMedGoogle Scholar
• Mitry D, Fleck BW, Wright AF, Campbell H, Charteris DG. Pathogenesis of rhegmatogenous retinal detachment: Predisposing anatomy and cell biology. Retina.30:1561–1572.
   Google Scholar
• Epstein RJ. Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors. Clin Breast Cancer. 2009;9:184–186.
   Web of Science ®Google Scholar
• Kobayashi H, Kobayashi K, Okinami S. Macular hole and myopic refraction. Br J Ophthalmol. 2002;86:1269–1273.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.
   PubMed Web of Science ®Google Scholar
• Din OS, Dodwell D, Wakefield RJ, Coleman RE. Aromatase inhibitor-induced arthralgia in early breast cancer: What do we know and how can we find out more? Breast Cancer Res Treat. 2010;120:525–538.
   PubMed Web of Science ®Google Scholar
• Madea B. Is there recent progress in the estimation of the postmortem interval by means of thanatochemistry? Forensic Sci Int. 2005;151:139–149.
   PubMed Web of Science ®Google Scholar
• Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett. 2007;29:17–25.
   PubMed Web of Science ®Google Scholar
• Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res. 2000;19:323–344.
   PubMed Web of Science ®Google Scholar
• Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol. 2009;27:4955–4960.
   Google Scholar
• Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008;26:3147–3152.
   PubMed Web of Science ®Google Scholar
• Magliano M. Menopausal arthralgia: Fact or fiction. Maturitas. 2010;67:29–33.
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003;86:225–230.
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Front Neuroendocrinol. 2001;22:185–212.
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncology. 2009;18:811–821.
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–66.
   PubMed Web of Science ®Google Scholar
• Tremere LA, Pinaud R. Brain-generated estradiol drives long-term optimization of auditory coding to enhance the discrimination of communication signals. J Neurosci.2011;31:3271–3289.
   Google Scholar
• Jenkins V, Low R, Mitra S. Hearing sensitivity in women following chemotherapy treatment for breast cancer: Results from a pilot study. Breast. 2009;18:279–283.
   PubMed Web of Science ®Google Scholar
• Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409–415.
   PubMed Web of Science ®Google Scholar
• Laroche M, Borg S, Lassoued S, De Lafontan B, Roche H. Joint pain with aromatase inhibitors: Abnormal frequency of Sjogren’s syndrome. J Rheumatol. 2007;34:2259–2263.
   PubMed Web of Science ®Google Scholar
• Smith JA, Vitale S, Reed GF, Grieshaber SA, Goodman LA, Vanderhoof VH, Calis KA, Nelson LM. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol. 2004;122:151–156.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Jensen RV, Suzuki T, Richards SM. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands? Mol Vis. 2009;15:1553–1572.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114–2119.
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, Pepose JS, Kosheleff V, Porreco A, Lemp MA. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010;51:6125–6130.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T, Jr., Barton D, Novotny P. Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. J Clin Oncol. 2009;27:2831–2837.
   PubMed Web of Science ®Google Scholar
• Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: A review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30:112–126.
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome p-450 mediated drug-drug interactions: An update. Curr Drug Metab. 2002;3:13–37.
   PubMed Web of Science ®Google Scholar
• Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: A review. CNS Drugs. 2010;24:501–526.
   PubMed Web of Science ®Google Scholar
• Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate. J Clin Psychiatry. 2004;65:959–965.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu K, Yuan H, Yu M. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther. 2009;25:163–171.
   PubMed Web of Science ®Google Scholar
• Nieminen T, Lehtimaki T, Maenpaa J, Ropo A, Uusitalo H, Kahonen M. Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67:237–245.
   PubMed Web of Science ®Google Scholar
• Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle glaucoma− a pilot study. J Ocul Pharmacol Ther. 2010;26:497–501.
   Google Scholar
• Wickham R. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol. 2010;8:10–15.
   Google Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: A review of the literature. Eye (Lond). 2006;20:407–416.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26:170–175.
   PubMed Web of Science ®Google Scholar
• Tang SC. Women and bone health: Maximizing the benefits of aromatase inhibitor therapy. Oncology. 79:13–26.
   Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34–41.
   PubMed Web of Science ®Google Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8:96–110.
   PubMedGoogle Scholar
• Santen RJ. Effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab. 2011;96:308–319.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Alexandrescu DT. Acute retinal pigment epithelial detachment secondary to pamidronate administration. J Oncol Pharm Pract. 2009;15:119–121.
   Google Scholar
• Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135:219–222.
   PubMed Web of Science ®Google Scholar
• Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380–4387.
   PubMed Web of Science ®Google Scholar
• Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453–475.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer. 2009;45:1909–1915.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13:503–514.
   PubMed Web of Science ®Google Scholar
• Haverbeke G, Pertile G, Claes C, Zeyen T. Posterior uveitis: An under-recognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtalmol. 2003;71–76.
   Google Scholar
• Zhang H, Zhang, JJ, Lin MA, et al. Effect of estrogen on the permeability of retinal blood vessel. Chinese Journal of Ocular Fundus Diseases. 2005;21:174–176.
   Google Scholar
• Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: A potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144:741–746.
   PubMed Web of Science ®Google Scholar
• Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, Freeman WR. The role of abnormal vitreomacular adhesion in age-related macular degeneration: Spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146:218–227.
   PubMed Web of Science ®Google Scholar
• Schulze S, Hoerle S, Mennel S, Kroll P. Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol. 2008;86:470–481.
   Google Scholar
• Nguyen BQ, Fife RS. Vitreous contains a cartilage-related protein. Exp Eye Res. 1986;43:375–382.
   PubMed Web of Science ®Google Scholar
• Maumenee IH. Vitreoretinal degeneration as a sign of generalized connective tissue diseases. Am J Ophthalmol. 1979;88:432–449.
   PubMed Web of Science ®Google Scholar
• Lee BB. Paths to colour in the retina. Clin Exp Optom. 2004;87:239–248.
   Google Scholar
• Sample PA, Johnson CA, Haegerstrom-Portnoy G, Adams AJ. Optimum parameters for short-wavelength automated perimetry. J Glaucoma. 1996;5:375–383.
   PubMed Web of Science ®Google Scholar
• Pugh EN, Jr., Mollon JD. A theory of the pi1 and pi3 color mechanisms of Stiles. Vision Res. 1979;19:293–312.
   PubMed Web of Science ®Google Scholar
• Tailby C, Szmajda BA, Buzas P, Lee BB, Martin PR. Transmission of blue (S) cone signals through the primate lateral geniculate nucleus. J Physiol. 2008;586:5947–5967.
   Google Scholar
• Roy S, Jayakumar J, Martin PR, Dreher B, Saalmann YB, Hu D, Vidyasagar TR. Segregation of short-wavelength-sensitive (S) cone signals in the macaque dorsal lateral geniculate nucleus. Eur J Neurosci. 2009;30:1517–1526.
   Web of Science ®Google Scholar
• Wade A, Augath M, Logothetis N, Wandell B. fMRI measurements of color in macaque and human. J Vis. 2008;8:1–19.
   Google Scholar
• Liu J, Wandell BA. Specializations for chromatic and temporal signals in human visual cortex. J Neurosci. 2005;25:3459–3468.
   Google Scholar